• WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metab

  2026-04-20

  WY-14643 (Pirinixic Acid) is a highly potent and selective agonist of PPARα, central to lipid metabolism and inflammation regulation. It demonstrates dual PPARα/γ activity in the low micromolar range and is widely employed in metabolic disorder research. Benchmarked animal studies show significant improvement in insulin sensitivity, lipid profiles, and reduction of inflammatory markers.

• Plk1 Regulation of p31comet and Mitotic Checkpoint Disassemb

  2026-04-19

  This study elucidates how Polo-like kinase 1 (Plk1) regulates the mitotic checkpoint by suppressing the disassembly of mitotic checkpoint complexes via phosphorylation of p31comet. These findings clarify a previously ambiguous control mechanism, with implications for understanding cell cycle fidelity and potential therapeutic targeting.

• Erastin as a Ferroptosis Research Tool: Mechanistic Depth &

  2026-04-18

  Explore how Erastin, a leading ferroptosis inducer, provides unprecedented mechanistic clarity and translational potential in cancer biology and oxidative stress research. This article uniquely bridges molecular action, biomarker selection, and practical assay optimization.

• Strategic Use of Mifepristone (RU486) in Translational Oncol

  2026-04-17

  Explore advanced applications of Mifepristone (RU486) in translational research, with mechanistic insights into tumor suppression, protocol optimization, and the evolving landscape of hormone receptor-targeted therapies. This article bridges experimental evidence, clinical relevance, and workflow strategy, highlighting APExBIO's offering and drawing from landmark findings in prostate cancer heterogeneity.

• Tigecycline: Applied Workflows for Multidrug-Resistant Bacte

  2026-04-16

  Tigecycline, a pioneering glycylcycline antibiotic, empowers researchers with robust experimental workflows against multidrug-resistant pathogens such as MRSA and CREC. This article dissects real-world use-cases, evidence-driven protocol enhancements, and troubleshooting strategies that drive success in complex resistance models.

• Thiazovivin as a ROCK Inhibitor in Stem Cell Workflows

  2026-04-15

  Thiazovivin addresses key technical barriers in induced pluripotent stem cell generation and human embryonic stem cell survival by inhibiting the ROCK signaling pathway. It is best applied where high-efficiency reprogramming or post-dissociation cell viability is required. Thiazovivin should not be used for diagnostic or clinical purposes.

• FK866 (APO866): Expanding NAMPT Inhibition Beyond Hematologi

  2026-04-14

  Explore how FK866 (APO866) revolutionizes cancer research as a selective NAMPT inhibitor. This article delivers deeper insight into its mechanism and highlights new translational opportunities in NAD metabolism and combination therapies.

• Spermine Tetrahydrochloride: Bridging Mechanism to Translati

  2026-04-13

  This article examines the mechanistic underpinnings and translational potential of Spermine tetrahydrochloride, highlighting its unique role in stabilizing biomolecular structures, enhancing NMDA receptor signaling research, and enabling next-generation workflows in neuroscience and structural biology. By synthesizing recent experimental results, best-practice protocols, and strategic guidance, we position APExBIO’s Spermine tetrahydrochloride as a cornerstone reagent for researchers seeking to bridge discovery and clinical solutions.

• Neuroinflammation and CGRP/SP-Piezo2 Axis in Trigeminal Allo

  2026-04-12

  Liao et al. (2026) identify a neuroinflammatory feedback loop involving the CGRP/SP-Piezo2 axis and Ca2+ signaling as a driver of mechanical allodynia in trigeminal neuralgia. This mechanistic insight links ATP-driven pathways to tactile hypersensitivity, highlighting novel targets for pain modulation.

• Synergistic CDK4/6 and BET Inhibition Suppresses PDAC Progre

  2026-04-12

  Gu et al. (2025) demonstrate that combined CDK4/6 and BET inhibition produces a synergistic antitumor effect in pancreatic ductal adenocarcinoma (PDAC) by modulating GSK3β-mediated Wnt/β-catenin signaling. Their work highlights the limitations of CDK4/6 monotherapy and proposes a mechanistically guided combination strategy relevant for overcoming PDAC proliferation and epithelial-to-mesenchymal transition.

• Cimetidine as a Histamine-2 Receptor Antagonist in Applied R

  2026-04-11

  Harness Cimetidine’s unique partial agonist properties for advanced blood-brain barrier and cancer research. This guide delivers actionable protocols, troubleshooting tips, and workflow upgrades based on the latest high-throughput screening innovations and APExBIO’s high-purity product.

• PF-04971729 (Ertugliflozin): Optimizing SGLT2 Inhibitor Work

  2026-04-11

  PF-04971729 (Ertugliflozin) enables precise renal glucose transport studies and novel neuroprotective investigations. This guide translates cutting-edge reference findings and protocol insights into actionable workflows for diabetes and neurodegeneration research.

• Prostaglandin E2 in Inflammation Research: Workflow, Appl...

  2026-04-10

  Prostaglandin E2 (PGE2) is a versatile EP receptor agonist vital for dissecting immune regulation, inflammation, and organ protection. This guide details advanced experimental workflows, strategic applications, and troubleshooting tips for maximizing research impact using APExBIO’s high-purity PGE2. Discover how leveraging this endogenous prostaglandin accelerates discovery in inflammation modulation, reproductive medicine, and cardiovascular homeostasis.

• 5-Methyl-CTP: Modified Nucleotide for Enhanced mRNA Stabi...

  2026-04-09

  5-Methyl-CTP delivers next-level mRNA stability and translation efficiency, acting as a cornerstone for robust in vitro transcription and mRNA-based therapeutics. This guide details optimized workflows, advanced experimental applications, and evidence-driven troubleshooting to empower high-impact gene expression research.

• Z-DEVD-FMK: Advanced Caspase-3 Inhibitor for Apoptosis Re...

  2026-04-08

  Unlock precise control over apoptotic and neuroprotective pathways with Z-DEVD-FMK, a robust, cell-permeable, irreversible caspase-3 inhibitor. Explore optimized workflows, troubleshooting strategies, and comparative insights that maximize reliability in cancer and neurodegeneration research.

406 records 18/28 page Previous Next First page 上5页 1617181920 下5页 Last page